3.6.21
Amyl Therapeutics closes €18.3 million
We had the pleasure of attending the First International AL Amyloidosis Meeting in Brussels on July 5-6, 2024. This two-day program offered a unique opportunity to explore all aspects of AL amyloidosis, with a particular focus on managing complications related to organ involvement. The event also provided valuable moments for patients and medical professionals to exchange insights and learn from each other’s experiences.